PANDA: Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial

Sponsor
Washington University School of Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT03978767
Collaborator
(none)
286
1
2
37.6
7.6

Study Details

Study Description

Brief Summary

A randomized non-inferiority trial of women with preeclampsia with severe features to determine if the addition of nonsteroidal anti-inflammatory drugs is inferior or non-inferior to standard analgesic bundles in their impact on postpartum hypertension.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

Recently published clinical guidelines for the care of women with hypertensive disorders recommended that nonsteroidal anti-inflammatory drugs (NSAIDs) should be withheld from patients with hypertension that persists for more than one day postpartum (1). This recommendation is based in data from the general medicine literature, which suggests a role of NSAIDs in precipitating hypertension in non-pregnant adults (2,3). It may also draw from previously published case reports of post-partum hypertension that were thought to be NSAID induced (4). There has been a paucity of data from the obstetric literature to support or rebuff this recommendation. As the opioid crisis worsens in the United States, additional attention and resources have focused on limiting the use of narcotic medications. The effective employment of non-opioid analgesics has been shown to reduce narcotic use (5). Ibuprofen and other NSAIDs are the most effective and most commonly prescribed analgesics for postpartum pain, but clinicians now find themselves stuck between these recommendations and their efforts to limit unnecessary opioid prescriptions.

The investigators propose a randomized controlled non-inferiority trial of women with preeclampsia comparing a postpartum analgesic protocol that includes NSAIDs, to one that excludes them. The central hypothesis is that NSAID use does not worsen hypertensive diseases of pregnancy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
286 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized non-inferiority clinical trialRandomized non-inferiority clinical trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Preeclampsia And Nonsteroidal Drugs for Analgesia (PANDA): a Randomized Non Inferiority Trial
Actual Study Start Date :
Jun 10, 2019
Anticipated Primary Completion Date :
May 27, 2022
Anticipated Study Completion Date :
Jul 27, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: NSAID Analgesic bundle

Ibuprofen 600mg PO q 6 hrs as needed for pain, Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain. In patients undergoing cesarean section, ketorolac 30mg IV q 6 hrs may be substituted as an IV alternative to ibuprofen for the first 24 hours after surgery

Drug: Ibuprofen 600 mg
NSAID pain medication to be used in the experimental bundle for postpartum analgesia

Drug: Ketorolac
NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section

Drug: Acetaminophen
Analgesic medication to be used in both treatment arms

Drug: Oxycodone
Analgesic medication to be used in both treatment arms

Active Comparator: NSAID free analgesic bundle

Acetaminophen 1000mg q 8 hrs as needed for pain, and Oxycodone 5 to 10 mg q 4 hrs as needed for pain.

Drug: Acetaminophen
Analgesic medication to be used in both treatment arms

Drug: Oxycodone
Analgesic medication to be used in both treatment arms

Outcome Measures

Primary Outcome Measures

  1. postpartum antihypertensive requirements [at the end of hospitalization, up to 7 days after randomization]

    measurement of anti-hypertensive requirements at time of discharge

Secondary Outcome Measures

  1. Postpartum pain scores [From randomization to 6 weeks after randomization]

    Evaluate the effect of NSAIDs on patient perception of pain

  2. Postpartum opioid use [From randomization to 6 weeks after randomization]

    Compare the opioid requirements in each arm

  3. Mean arterial blood pressure [From randomization to 6 weeks after randomization]

    Compare peak, average and median MAPs postpartum

  4. End organ damage [during hospitalization, an average of 4 days]

    Evaluate for evidence of renal, hepatic or neurological injury in the poatpartum period

  5. Hospital readmission [From randomization to 6 weeks after randomization]

    Evaluate the incidence of hospital readmission rate postpartum

  6. Continued anti-hypertensive requirement [up to 6 weeks]

    evaluate the need for antihypertensive medications at 6 weeks postpartum

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women at > 23 weeks gestational age undergoing vaginal or cesarean delivery at
Barnes-Jewish Hospital with:
  • An antepartum diagnosis of preeclampsia with severe features

  • Pre-eclampsia with severe features will be defined as:

  • Elevated blood pressure ≥ 160/110, or

  • Pre-eclampsia in the setting of thrombocytopenia (platelet count < 100,000), or

  • Impaired liver function (AST elevated to twice upper limit of normal), or

  • Persistent epigastric pain, or

  • Renal insufficiency (serum creatinine of 1.1 mg/dl or doubling of prior value), or

  • Pulmonary edema, or

  • New onset visual disturbance or headache unresponsive to therapy.

Exclusion Criteria:
  • NSAID allergy

  • Allergy to acetaminophen

  • Antihypertensive use in this pregnancy prior to 20 weeks gestation

  • Chronic kidney disease or Acute kidney injury with Creatine clearance less than 60 mL/min

  • Inability to obtain consent

  • Opioid abuse disorder

  • Peptic ulcer disease.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Barnes Jewish Hospital Saint Louis Missouri United States 63110

Sponsors and Collaborators

  • Washington University School of Medicine

Investigators

None specified.

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Jonathan (Jake) Hirshberg, Clinical Fellow, Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT03978767
Other Study ID Numbers:
  • 201901202
First Posted:
Jun 7, 2019
Last Update Posted:
Oct 13, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Jonathan (Jake) Hirshberg, Clinical Fellow, Washington University School of Medicine
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 13, 2021